Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: The role of Na+K+-ATPase/cSRC pathway

Journal of Hypertension

Volumn 32, Issue 3, 2014, Pages 542-554

  Wenceslau, Camilla F ^a   Rossoni, Luciana V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Hypertension; Ouabain; Oxidative stress; Resistance arteries

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); CYCLOOXYGENASE 2; NITRIC OXIDE; OUABAIN; PROTEIN KINASE P60; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ROSTAFUROXIN; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; BLOOD VESSEL INJURY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DEOXYCORTICOSTERONE-SALT INDUCED HYPERTENSION; DRUG BIOAVAILABILITY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MALE; MESENTERIC ARTERY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT; RESISTANCE BLOOD VESSEL; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WESTERN BLOTTING;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CYCLOOXYGENASE 2; DESOXYCORTICOSTERONE ACETATE; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; MALE; MESENTERIC ARTERIES; NADPH OXIDASE; OUABAIN; OXIDATIVE STRESS; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; SODIUM CHLORIDE, DIETARY; SODIUM-POTASSIUM-EXCHANGING ATPASE; SRC-FAMILY KINASES; VASCULAR RESISTANCE; VASODILATION;

EID: 84894101614     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000059     Document Type: Article

References (46)

1. Blaustein MP. Physiological effects of endogenous ouabain: control of intra-celular Ca2 stores and cell responsiveness. Am J Physiol 1993; 264:C1367-C1387.
2. Blaustein MP, Juhaszova M, Golovina VA. The cellular mechanism of action of cardiotonic steroids: a new hypothesis. Clin Exp Hypertens 1998; 20:691-703.
3. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. Am J Physiol 1998; 275:F633-F650.
4. Lingrel JB. The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na,K-ATPase. Annu Rev Physiol 2010; 72:395-412.
5. Xie Z, Kometiani P, Liu J, Li J, Shapiro JI, Askari A. Intracellular reactive oxygen species mediate the linkage of Na-K-ATPase to hypertrophy and its marker genes in cardiac myocytes. J Biol Chem 1999; 274:19323-19328.
6. Xie Z, Cai T. Na-K-ATPase-mediated signal transduction: from protein interaction to cellular function. Mol Interv 2003; 3:157-168.
7. Gottlieb SS, Rogowski AC, Weinberg M, Krichten CM, Hamilton BP, Hamlyn JM. Elevated concentration of endogenous ouabain in patients with congestive heart failure. Circulation 1992; 86:420-425.
8. Haddy FJ, Overbeck HW. The role of humoral agents in volume expanded hypertension. Life Sci 1976; 19:935-947.
9. Hamlyn JM, Ringel R, Schaeffer J, Levinson PD, Hamilton BP, Kowarski AA, Blaustein MP. A circulating inhibitor of (Na,K)-ATPase associated with essential hypertension. Nature 1982; 300:650-652.
10. Pitzalis MV, Hamlyn JM, Messaggio E, Iacoviello M, Forleo C, Romito R, et al. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur J Heart Fail 2006; 8:179-186.
11. Stella P, Manunta P, Mallamaci F, Melandri M, Spotti D, Tripepi G, et al. Endogenous ouabain and cardiomyopathy in dialysis patients. J Intern Med 2008; 263:274-280.
12. Rossi G, Manunta P, Hamlyn JM, Pavan E, De Toni R, Semplicini A, Pessina AC. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J Hypertens 1995; 13:1181-1191.
13. Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnant women. J Clin Endocrinol Metab 1984; 59:1070-1074.
14. Blanco G, Wallace DP. Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2013; 305:F797-812.
15. Yuan CM, Manuta P, Hamlyn JM, Chen S, Bohen E, Yeun J, et al. Longterm ouabain administration produces hypertension in rats. Hypertension 1993; 22:178-187.
16. Manunta P, Hamilton J, Rogowski AC, Hamilton BP, Hamlyn JM. Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertens Res 2000; 23 (Suppl):S77-S85.
17. Rossoni LV, Salaices M, Marín J, Vassallo DV, Alonso MJ. Alterations in phenylephrine-induced contractions and the vascular expression of Na,K-ATPase in ouabain-induced hypertension. Br J Pharmacol 2002; 135:771-781.
18. Rossoni LV, Salaices M, Miguel M, Briones AM, Barker LA, Vassallo DV, et al. Ouabain-induced hypertension is accompanied by increases in endothelial vasodilator factors. Am J Physiol Heart Circ Physiol 2002; 283:H2110-H2118.
19. Xavier FE, Salaices M, Marquez-Rodas I, Alonso MJ, Rossoni LV, Vassallo DV, et al. Neurogenic nitric oxide release increases in mesenteric arteries from ouabain hypertensive rats. J Hypertens 2004; 22:949-957.
20. Xavier FE, Rossoni LV, Alonso MJ, Balfagón G, Vassallo DV, Salaices M. Ouabain-induced hypertension alters the participation of endothelial factors in (-adrenergic responses differently in rat resistance and conductance mesenteric arteries. Br J Pharmacol 2004; 143:215-225.
21. Xavier FE, Yogi A, Callera GE, Tostes RC, Alvarez Y, Salaices M, et al. Contribution of the endothelin and renin angiotensin systems to the vascular changes in rats chronically treated with ouabain. Br J Pharmacol 2004; 143:794-802.
22. Briones AM, Xavier FE, Arribas SM, González MC, Rossoni LV, Alonso MJ, Salaices M. Alterations in structure and mechanics of resistance arteries from ouabain induced hypertensive rats. Am J Physiol Heart Circ Physiol 2006; 291:H193-H201.
23. Wenceslau CF, Davel AP, Xavier FE, Rossoni LV. Long-term ouabain treatment impairs vascular function in resistance arteries. J Vasc Res 2011; 48:316-326.
24. Huang BS, Huang X, Harmsen E, Leenen FH. Chronic central versus peripheral ouabain blood pressure, and sympathetic activity in rats. Hypertension 1994; 23:1087-1090.
25. Kurashina T, Kirchner KA, Granger JP, Patel AR. Chronic sodiumpotassium- ATPase inhibition with ouabain impairs renal haemodynamics and pressure natriuresis in the rat. Clin Sci 1996; 91:497-502.
26. Rossoni LV, Xavier FE, Moreira CM, Falcochio D, Amanso AM, Tanoue CU, et al. Ouabain-induced hypertension enhances left ventricular contractility in rats. Life Sci 2006; 79:1537-1545.
27. Xavier FE, Davel AP, Fukuda LE, Rossoni LV. Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens 2009; 27:1233-1242.
28. Ferrari P, Torielli L, Ferrandi M, Padoani G, Duzzi L, Florio M, et al. PST2238: a new antihypertensive compound that antagonizes the longterm pressor effect of ouabain. J Pharmacol Exp Ther 1998; 285:83-94.
29. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST 2238. J Biol Chem 2004; 279:33306-33314.
30. Ferrandi M, Molinari I, Torielli L, Padoani G, Salardi S, Rastaldi MP, et al. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies. Sci Transl Med 2010; 2:59ra86.
31. Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: a ouabain antagonist that corrects renal and vascular Na-K-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physio 2006; 290:R529-535.
32. Mulvany MJ, Halpern W. Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977; 41:19-26.
33. Webb RC, Bohr DF. Potassium-induced relaxation as an indicator of NaKATPase activity in the vascular smooth muscle. Blood Vessels 1978; 15:198-207.
34. Hamlyn JM, Manunta P. Endogenous ouabain: a link between sodium intake and hypertension. Curr Hypertens Rep 2011; 13:14-20.
35. Manunta P, Stella P, Rivera R, Ciurlino D, Cusi D, Ferrandi M, et al. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 1999; 4:450-456.
36. Doris PA. Ouabain in plasma from spontaneously hypertensive rats. Am J Physiol Renal Physiol 1994; 266:H360-H364.
37. Kojima I. Circulating digitalis-like substance is increased in DOCA-salt hypertension. Biochem Biophys Res Commun 1984; 122:129-136.
38. Lanzani C, Citterio L, Glorioso N, Manunta P, Tripodi G, Salvi E, et al. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies. Sci Transl Med 2010; 2:59ra87.
39. Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 2004; 44:248-252.
40. Aizman O, Uhlén P, Lal M, Brismar H, Aperia A. Ouabain, a steroid hormone that signals with slow calcium oscillations. Proc Natl Acad Sci 2001; 98:13420-13424.
41. Valente RC, Capella LS, Monteiro RQ, Rumjanek VM, Lopes AG, Capella MAM. Mechanisms of ouabain toxicity. Faseb J 2003; 17:1700-1702.
42. Fukai T, Siegfried MR, Ushio-Fukai M, Griendling KK, Harrison DG. Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension. Circ Res 1999; 85:23-28.
43. Bedard K, Krause KH. The NOX family of ROS-generating NAD(P)H oxidases: physiology and pathophysiology. Physiol Rev 2007; 87:245-313.
44. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 2002; 91:406-413.
45. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005; 288:H1016-H1021.
46. Sancho P, Martín-Sanzb P, Fabregata I. Reciprocal regulation of NADPH oxidases and the cyclooxygenase-2 pathway. Free Radic Biol Med 2011; 51:1789-1798.